Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...
A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...
The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
